Inhibition of fructose 1,6-bisphosphatase reduces excessive endogenous glucose production and attenuates hyperglycemia in Zucker diabetic fatty rats

Diabetes

Volumn 55, Issue 6, 2006, Pages 1747-1754

  Van Poelje, Paul D ^a   Potter, Scott C ^a   Chandramouli, Visvanathan C ^b   Landau, Bernard R ^b   Dang, Qun ^a   Erion, Mark D ^a  

^a Metabasis Therapeutics Inc   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FBPase, fructose 1,6 bisphosphatase; NEFA, nonesterified free fatty acid

Indexed keywords

ENZYME INHIBITOR; FRUCTOSE BISPHOSPHATASE; GLUCOSE; GLYCOGEN; LACTIC ACID; MB 06322; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOGEN STORAGE DISEASE; HYPERGLYCEMIA; LIPID DIET; MALE; NONHUMAN; PANCREAS FUNCTION; PRIORITY JOURNAL; RAT; RAT STRAIN;

ALANINE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; EATING; FEMALE; FRUCTOSE-BISPHOSPHATASE; GLUCONEOGENESIS; GLUCOSE; HYPERGLYCEMIA; INSULIN; KETONE BODIES; LACTIC ACID; MALE; MOLECULAR STRUCTURE; ORGANOPHOSPHORUS COMPOUNDS; PANCREAS; RATS; RATS, ZUCKER; TRIGLYCERIDES;

EID: 33748286778     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db05-1443     Document Type: Article

References (50)

1. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM: Receptor and post-receptor defects contribute to the insulin resistance in non-insulin dependent diabetes mellitus. J Clin Invest 68:957-969, 1981
2. DeFronzo RA, Ferrannini E, Simonson DC: Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 38:387-395, 1989
3. Consoli A, Nurjhan N, Capani F, Gerich J: Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes 38:550-557, 1989
4. 13C nuclear magnetic resonance study. J Clin Invest 90:1323-1327, 1992
5. Wajngot A, Chandramouli V, Schumann WC, Ekberg K, Jones PK, Efendic S, Landau BR: Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metabolism 50:47-52, 2001
6. Basu R, Chandramouli V, Dicke B, Landau B, Rizza R: Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis. Diabetes 54:1942-1948, 2005
7. Firth RG, Bell PM, Marash HM, Hansen I, Rizza RA: Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus: role of hepatic and extrahepatic tissues. J Clin Invest 77:1525-1532, 1986
8. Mitrakou A, Kelley D, Mokan M, Veneman T, Pangburn T, Relly J, Gerich J: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29, 1992
9. Singhal P, Caumo A, Carey PE, Cobelli C, Taylor R: Regulation of endogenous glucose production after a mixed meal in type 2 diabetes. Am J Physiol Endocrinol Metab 283:E275-E283, 2002
10. Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM: Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes 43:1440-1444, 1994
11. Perriello G, Pampanelli S, Del Sindaco P, Lalli C, Ciofetta M, Volpi E, Santeusanio F, Brunetti P, Bolli GB: Evidence of increased systemic glucose production and gluconeogenesis in an early stage of NIDDM. Diabetes 46:1010-1016, 1997
12. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA, Inzucchi S, Kelley D, Nolan J, Olefsky JM, Polonsky KS, Silver D, Valiquett TR, Shulman GI: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:176-185, 1998
13. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069, 2000
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
15. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, Taylor K, Kim D, Aisporna M, Wang Y, Baron AD: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88:3082-3089, 2003
16. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661-1669, 1996
17. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
18. Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, Yki-Jarvinen H: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176, 2004
19. Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes (Review). Diabetes Care 26:2929-2940, 2003
20. Madsen P, Knudsen LB, Wiberg FC, Carr RD: Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 41:5150-5157, 1998
21. Jacobson PB, von Geldern TW, Ohman L, Osterland M, Wang J, Zinker B, Wilcox D, Nguyen PT, Mika A, Fung S, Fey T, Goos-Nilsson A, Grynfarb M, Barkhem T, Marsh K, Beno DW, Nga-Nguyen B, Kym PR, Link JT, Tu N, Edgerton DS, Cherrington A, Efendic S, Lane BC, Opgenorth TJ: Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther 314:191-200, 2005
22. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB: Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144:4755-4762, 2003
23. Mayers RM, Butlin RJ, Kilgour E, Leighton B, Martin D, Myatt J, Orme JP, Holloway BR: AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2 (PDHK2), activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese (fa/fa) Zucker rats. Biochem Soc Trans 31:1165-1167, 2003
24. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF: Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370-373, 2003
25. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL: Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci U S A 95:1776-1781, 1998
26. Arion WJ, Canfield WK, Ramos FC, Su ML, Burger HJ, Hemmerle H, Schubert G, Below P, Herling AW: Chlorogenic acid analogue S 3483: a potent competitive inhibitor of the hepatic and renal glucose-6-phosphatase systems. Arch Biochem Biophys 351:279-285, 1998
27. Foley LH, Wang P, Dunten P, Ramsey G, Gubler ML, Wertheimer SJ: Modified 3-alkyl-1,8-dibenzylxanthines as GTP-competitive inhibitors of phosphoenolpyruvate carboxykinase. Bioorg Med Chem Lett 13:3607-3610, 2003
28. Erion MD, van Poelje PD, Dang Q, Kasibhatla SR, Potter SC, Reddy MR, Reddy KR, Jiang T, Lipscomb WN: MB06322 (CS-917): a potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. Proc Natl Acad Sci U S A 102:7970-7975, 2005
29. Terrettaz J, Jeanrenaud B: In vivo hepatic and peripheral insulin resistance in genetically obese (fa/fa) rats. Endocrinology 112:1346-1351, 1983
30. Landau BR, Wahren J, Chandramouli V, Schumann WC, Ekberg K, Kalhan SC: Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 98:378-385, 1996
31. 2O administration. Anal Biochem 297:195-197, 2001
32. Steele R: Influences of glucose loading and injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
33. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911-917, 1959
34. Seifter S, Muntwyler E, Harkness DM: Some effects of continued protein deprivation, with and without methionine supplementation, on intracellular liver components. Proc Soc Exp Biol Med 75:46-50, 1950
35. Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau BR, Ferrannini E: Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 49:1367-1373, 2000
36. Potter SC, van Poelje PD, Effenberger K, Erion MD: Evidence implicating gluconeogenesis inhibition as the mechanism by which MB06322 lowers blood glucose in vivo (Abstract). Diabetes 53 (Suppl. 2):A364, 2004
37. Jenssen T, Nurjhan N, Consoli A, Gerich JE: Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. J Clin Invest 86:489-497, 1990
38. Boden G, Chen X, Capulong E, Mozzoli M: Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes. Diabetes 50:810-816, 2001
39. Gastaldelli A, Miyazaki Y, Pettiti M, Buzzigoli E, Mahankali S, Ferrannini E, DeFronzo RA: Separate contribution of diabetes, total fat mass, and fat topography to glucose production, gluconeogenesis, and glycogenolysis. J Clin Endocrinol Metab 89:3914-3921, 2004
40. Puhakainen I, Koivisto VA, Yki-Jarvinen H: No reduction in total hepatic glucose output by inhibition of gluconeogenesis with ethanol in NIDDM patients. Diabetes 40:1319-1327, 1991
41. Siler SQ, Neese RA, Christiansen MP, Hellerstein MK: The inhibition of gluconeogenesis following alcohol in humans. Am J Physiol 275:E897-E907, 1998
42. Erion MD, Potter SC, van Poelje PD: Fructose 1,6-bisphosphatase inhibition improves oral glucose tolerance and enhances the antidiabetic action of glyburide in the Zucker diabetic fatty rat (Abstract). Diabetologia 47 (Suppl. 1): PS-796, 2004
43. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48:1415-1424, 1999
44. Corsetti JP, Sparks JD, Peterson RG, Smith RL, Sparks CE: Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 148:231-241, 2000
45. Boden G: Free fatty acids and insulin secretion in humans. Curr Diab Rep 5:167-170, 2005
46. Pickavance LC, Brand CL, Wassermann K, Wilding JPH: The dual PPARα/γ agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 144:308-316, 2005
47. Pold R, Jensen LS, Jessen N, Buhl ES, Schmitz O, Flyvbjerg A, Fujii N, Goodyear LJ, Gotfredsen CF, Brand CL, Lund S: Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 54:928-934, 2005
48. Zawadzki JK, Wolfe RR, Mott DM, Lillioja S, Howard BV, Bogardus C: Increased rate of Cori cycle in obese subjects with NIDDM and effect of weight reduction. Diabetes 37:154-159, 1988
49. 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. J Clin Invest 97:126-132, 1996
50. van Poelje PD, Potter SC, Topczeski E, Hou J, Linemeyer DL, Erion MD: Comparative metabolic effects of a novel fructose 1,6-bisphosphatase inhibitor and metformin in the female ZDF rat (Abstract). Diabetologia 48 (Suppl. 1):PS-765, 2005